New Prospective Study Shows Significant Reduction In Reports Of Postoperative Halos From Patients Treated With TearScience LipiFlow Treatment Prior To Bilateral Cataract Surgery

SANTA ANA, Calif., July 24, 2021 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery....

from PR Newswire: https://ift.tt/3wXB13L